Abstract
Vitamin C (ascorbate) is toxic to tumour cells, and has been suggested as an adjuvant cancer treatment. Our goal was to determine if ascorbate, in combination with other antioxidants, could kill cells in the SW620 hollow fibre in vitro solid tumour model at clinically achievable concentrations. Ascorbate anti-cancer efficacy, alone or in combination with lipoic acid, vitamin K3, phenyl ascorbate, or doxorubicin, was assessed using annexin V staining and standard survival assays. 2-day treatments with 10 mM ascorbate increased the percentage of apoptotic cells in SW620 hollow fibre tumours. Lipoic acid synergistically enhanced ascorbate cytotoxicity, reducing the 2-day LC50 in hollow fibre tumours from 34 mM to 4 mM. Lipoic acid, unlike ascorbate, was equally effective against proliferating and non-proliferating cells. Ascorbate levels in human blood plasma were measured during and after intravenous ascorbate infusions. Infusions of 60 g produced peak plasma concentrations exceeding 20 mM with an area under the curve (24 h) of 76 mM h. Thus, tumoricidal concentrations may be achievable in vivo. Ascorbate efficacy was enhanced in an additive fashion by phenyl ascorbate or vitamin K3. The effect of ascorbate on doxorubicin efficacy was concentration dependent; low doses were protective while high doses increased cell killing. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Agus DB, Vera JC and Golde DW (1999) Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res 59: 4555–4558
Benade L, Howard T and Burk D (1969) Synergistic killing of Ehrlich ascites carcinoma cells by ascorbate and 3-amino-1,2,4,-triazole. Oncology 23: 33–43
Bram S, Froussard P, Guichard M, Jasmin C, Augery Y, Sinoussi-Barre F and Wray W (1980) Vitamin C preferential toxicity for malignant melanoma cells. Nature 284: 629–631
Cameron E and Campbell A (1974) The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9: 285–315
Cameron E and Pauling L (1976) Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73: 3685–3689
Cameron E, Pauling L and Leibovitz B (1979) Ascorbic acid and cancer: a review. Cancer Res 39: 663–681
Casciari JJ, Hollingshead MG, Alley MC, Mayo JG, Malspeis L, Miyauchi S, Grever MR and Weinstein JN (1994) Growth and chemotherapeutic response of cells in a hollow fiber in vitro solid tumor model. J Natl Cancer Inst 86: 1846–1852
Collins JM (1996) Pharmacokinetics and clinical monitoring. In: Cancer Chemotherapy and Biotherapy, Chabner BA, Longo DL (eds) pp 17–30. Lippincott-Raven Publishers: Philadelphia
Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J and Frytak S (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301: 687–690
Fujita K, Shinpo K, Yamada K, Sato T, Niimi H, Shamoto M, Nagatsu T, Takeuchi T and Umezawa H (1982) Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res 42: 309–316
Goldschmidt MC (1991) Reduced bactericidal activity in neutrophils from scorbutic animals and the effect of ascorbic acid on these target bacteria in vivo and in vitro. Am J Clin Nutr 54: 1214S–1220S
Henry RJ, Cannon DC and Winkleman JW (1974) Determination of Ascorbic Acid. In: Clinical Chemistry: Principles and Techniques pp 1393–1398. Harper & Row: New York
Henson DE, Block G and Levine M (1991) Ascorbic acid: biologic functions and relation to cancer. J Natl Cancer Inst 83: 547–550
Hornig D (1975) Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann N Y Acad Sci 258: 103–118
Jackson JA, Riordan HD, Hunninghauke RE and Riordan N (1995) High dose intravenous vitamin C and long time survival of a patient with cancer of the head of the pancreas. J Ortho Med 10: 87–88
Jonas SK, Riley PA and Willson RL (1989) Hydrogen peroxide cytotoxicity: low-temperature enhancement by ascorbate or reduced lipoate. Biochem J 265: 651–655
Koch CJ and Biaglow JE (1978) Toxicity, radiation sensitivity modification, and metabolic effects of dehydroascorbate and ascorbate in mammalian cells. J Cell Physiol 94: 299–306
Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D and Bruckner HW (1996) Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183–189
Langemann H, Torhorst J, Kabiersch A, Krenger W and Honegger CC (1989) Quantititve determination of water and lipid soluble antioxidants in neoplastic and non-neoplastic human breast tissue. Int. J. Cancer 43: 1169–1173
Leung PY, Miyashita K, Young M and Tsao CS (1993) Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 13: 475–480
Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ and Ames MM (1985) High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312: 137–141
Murata A, Morishige F and Yamaguchi H (1982) Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl 23: 103–113
Noto V, Taper HS, Jiang YH, Janssens J, Bonte J and De Loecker W (1989) Effects of sodium ascorbate (vitamin C) and 2-methyl-1,4-naphthoquinone (vitamin K3) treatment on human tumor cell growth in vitro. I. Synergism of combined vitamin C and K3 action. Cancer 63: 901–906
Okunieff P and Suit HD (1987) Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine fibrosarcomas. J Natl Cancer Inst 79: 377–381
Ou P, Tritschler HJ and Wolff SP (1995) Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant?. Biochemical Pharmacology 50: 123–126
Penn ND, Purkins L, Kelleher J, Heatley RV, Mascie-Taylor BH and Belfield PW (1991) The effect of dietary supplementation with vitamins A, C and E on cell-mediated immune function in elderly long-stay patients: a randomized controlled trial. Age Ageing 20: 169–174
Raloff J (2000) Antioxidants may help cancers thrive. Science News 157: 5
Riordan HD, Jackson JA, Riordan NH and Schultz M (1998) High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J Ortho Med 13: 72–73
Riordan HR, Jackson JA and Schultz M (1990) Case study: high-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney. J Ortho Med 5: 5–7
Riordan NH, Riordan HD, Meng X, Li Y and Jackson JA (1995) Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44: 207–213
Taper HS, Keyeux A and Roberfroid M (1996) Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 16: 499–503
Tsao CS, Dunham WB and Leung PY (1988) In vivo antineoplastic activity of ascorbic acid for human mammary tumor. In Vivo 2: 147–150
Varga JM and Airoldi L (1983) Inhibition of transplantable melanoma tumor development in mice by prophylactic administration of Ca-ascorbate. Life Sci 32: 1559–1564
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Casciari, J., Riordan, N., Schmidt, T. et al. Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer 84, 1544–1550 (2001). https://doi.org/10.1054/bjoc.2001.1814
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1814
Keywords
This article is cited by
-
Alternative medicine: therapeutic effects on gastric original signet ring carcinoma via ascorbate and combination with sodium alpha lipoate
BMC Complementary Medicine and Therapies (2022)
-
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution
Cancer Immunology, Immunotherapy (2021)
-
Examination of the physicochemical properties of caffeic acid complexed with γ-cyclodextrin
Journal of Inclusion Phenomena and Macrocyclic Chemistry (2015)
-
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients
Journal of Translational Medicine (2013)
-
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer
Cancer Chemotherapy and Pharmacology (2013)